MedPath

A randomised, double blind, placebo-controlled cross-over study to investigate the effects of intravenous S(+)-ketamine on functional brain connectivity using fMRI in healthy volunteers.

Completed
Conditions
fMRI onderzoek in gezonde vrijwilligers
not applicable
Registration Number
NL-OMON34353
Lead Sponsor
eids Universitair Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
12
Inclusion Criteria

healthy volunteers
age 18-45
right handed
naive to Ketanest-S

Exclusion Criteria

Obesity (BMI > 30);
Significant history of any cardiac or vascular disorder, asthma or other pulmonary disease, major gastrointestinal abnormalities, peptic ulceration, hepatic, neurological, psychiatric, haematological (including bleeding disorders), endocrine, renal, or major genitourinary disease.
History of illness, condition or medication use that, in the opinion of the investigator, might interfere with optimal participation, confound the results of the study or pose additional risk in administering S(+)-ketamine to the subject or in making the MRIs
History of chronic alcohol or illicit drug use;
Unable to refrain from quinine containing products and grapefruit or grapefruit juice from 7 days prior to study start until the last study day.
Metal medical devices like pacemakers, knee or hip prosthesis, ear implants, vessel clips, subcutaneous insulin pumps or carries metal particles (e.g. metal splinter in the eye) inside the body.
Claustrophobia.
Allergy to study medications;
Not able to maintain a regular diurnal rhythm.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>resting state network (fMRI)</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>arterial spin labeling (fMRI)<br /><br>plasma concentrations of S(+)-ketamine and S(+)-norketamine<br /><br>pain relief<br /><br>side effects</p><br>
© Copyright 2025. All Rights Reserved by MedPath